Ninety-four percent (94%) of neurological drugs fail when tested in humans because traditional animal models don’t capture the complexity of neurological diseases and generate results that don’t translate to humans. As such, many drugs showing promise preclinically fail when tested in humans due to toxicity or efficacy issues.

In contrast, AxoSim's products show over 90% accuracy in measuring human outcomes compared to 30% in traditional animal models.

AxoSim focuses on both the central and peripheral nervous system with applications in neurotoxicology and drug discovery for neuropathies, pain, epilepsies, de-myelinating diseases, neurodegenerative diseases, neurodevelopmental disorders, neuromuscular disorders, and neuroinflammation.


Central nervous system

microBrain™ is an in vitro model of the central nervous system comprising neurons, astrocytes, and microglia, delivering clinically-translational electrophysiology, including spontaneous network activity.

BrainSim® is an in vitro model of the central nervous system comprising neurons, astrocytes, microglia, and highlighted with oligodendrocytes and myelination, delivering clinically-translational electrophysiology, including coordinated network activity.


Peripheral nervous system

NerveSim® is an in vitro model of the peripheral nervous system comprising sensory neurons and Schwann cells or motor neurons and astrocytes, delivering clinically-translational electrophysiology, including nerve conduction studies.